Literature DB >> 2179584

Oral immunotherapy in paraplegic patients with chronic urinary tract infections: a double-blind, placebo-controlled trial.

H J Hachen1.   

Abstract

In a 6-month, double-blind, placebo-controlled clinical trial with cross-over, we investigated the efficacy and tolerance of an orally administered bacterial extract in 70 spinal cord injury patients with chronic lower urinary tract infections. In the treated patients, compared to those given placebo, there was a statistically significant decrease in the degree of bacteriuria, a considerably decreased incidence of infectious episodes and a lesser requirement for antibiotics.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2179584     DOI: 10.1016/s0022-5347(17)40084-x

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  10 in total

1.  Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit.

Authors:  A Rudin; G C Riise; J Holmgren
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

2.  [Homeopathic prophylaxis of urinary tract infections in patients with neurogenic bladder dysfunction].

Authors:  J Pannek; M C Jus; M S Jus
Journal:  Urologe A       Date:  2012-04       Impact factor: 0.639

Review 3.  Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine.

Authors:  Ariel R Brumbaugh; Harry L T Mobley
Journal:  Expert Rev Vaccines       Date:  2012-06       Impact factor: 5.217

4.  Anti-inflammatory effect of an Escherichia coli extract in a mouse model of lipopolysaccharide-induced cystitis.

Authors:  Seung-Ju Lee; Sae Woong Kim; Yong-Hyun Cho; Moon Soo Yoon
Journal:  World J Urol       Date:  2005-12-31       Impact factor: 4.226

Review 5.  Waging war against uropathogenic Escherichia coli: winning back the urinary tract.

Authors:  Kelsey E Sivick; Harry L T Mobley
Journal:  Infect Immun       Date:  2009-11-16       Impact factor: 3.441

Review 6.  Systematic review and practice policy statements on urinary tract infection prevention in adults with spina bifida.

Authors:  Michael Tradewell; Joseph J Pariser; Tony Nimeh; Sean P Elliott
Journal:  Transl Androl Urol       Date:  2018-05

7.  Uro-Vaxom® versus placebo for the prevention of recurrent symptomatic urinary tract infections in participants with chronic neurogenic bladder dysfunction: a randomised controlled feasibility study.

Authors:  Derick Wade; James Cooper; Fadel Derry; Julian Taylor
Journal:  Trials       Date:  2019-04-16       Impact factor: 2.279

8.  Usefulness of classical homeopathy for the prophylaxis of recurrent urinary tract infections in individuals with chronic neurogenic lower urinary tract dysfunction.

Authors:  Jürgen Pannek; Susanne Pannek-Rademacher; Mohinder S Jus; Jens Wöllner; Jörg Krebs
Journal:  J Spinal Cord Med       Date:  2018-02-27       Impact factor: 1.985

Review 9.  Management of urinary tract infections in patients with neurogenic bladder: challenges and solutions.

Authors:  Jürgen Pannek; Jens Wöllner
Journal:  Res Rep Urol       Date:  2017-07-11

10.  Immunotherapy to reduce frequency of urinary tract infections in people with neurogenic bladder dysfunction; a pilot randomised, placebo-controlled trial.

Authors:  Derick T Wade; James Cooper; Nicholas Peckham; Maurizio Belci
Journal:  Clin Rehabil       Date:  2020-08-07       Impact factor: 3.477

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.